Lou Yuanmei, Basha Genc, Seipp Robyn P, Cai Bing, Chen Susan S, Moise Alexander R, Jeffries Andrew P, Gopaul Ray S, Vitalis Timothy Z, Jefferies Wilfred A
Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.
Clin Cancer Res. 2008 Mar 1;14(5):1494-501. doi: 10.1158/1078-0432.CCR-07-1066.
Tpn is a member of the MHC class I loading complex and functions to bridge the TAP peptide transporter to MHC class I molecules. Metastatic human carcinomas often express low levels of the antigen-processing components Tapasin and TAP and display few functional surface MHC class I molecules. As a result, carcinomas are unrecognizable by effector CTLs. The aim of this study is to examine if Tapasin (Tpn) plays a critical role in the escape of tumors from immunologic recognition.
To test our hypothesis, a nonreplicating adenovirus vector encoding human Tpn (AdhTpn) was constructed to restore Tpn expression in vitro and in vivo in a murine lung carcinoma cell line (CMT.64) that is characterized by down-regulation of surface MHC class I due to deficiency in antigen-processing components.
Ex vivo, Tpn expression increased surface MHC class I and restored susceptibility of tumor cells to antigen-specific CTL killing, and AdhTpn infection of dendritic cells also significantly increased cross-presentation and cross-priming. Furthermore, tumor-bearing animals inoculated with AdhTpn demonstrated a significant increase in CD8(+) and CD4(+) T cells and CD11c(+) dendritic cells infiltrating the tumors. Provocatively, whereas syngeneic mice bearing tumors that were inoculated with AdhTpn a significant reduction in tumor growth and increased survival compared with vector controls, combining AdhTpn inoculation with AdhTAP1 resulted in a significant augmentation of protection from tumor-induced death than either component alone.
This is the first demonstration that Tpn alone can enhance survival and immunity against tumors but additionally suggests that Tpn and TAP should be used together as components of immunotherapeutic vaccine protocols to eradicate tumors.
Tpn是MHC I类装载复合体的成员,其作用是将TAP肽转运体与MHC I类分子连接起来。转移性人类癌通常表达低水平的抗原加工成分TAPasin和TAP,且功能性表面MHC I类分子很少。因此,癌无法被效应性CTL识别。本研究的目的是检验TAPasin(Tpn)在肿瘤逃避免疫识别中是否起关键作用。
为验证我们的假设,构建了一种编码人Tpn的非复制性腺病毒载体(AdhTpn),以在体外和体内恢复鼠肺癌细胞系(CMT.64)中的Tpn表达,该细胞系由于抗原加工成分缺乏而表面MHC I类下调。
在体外,Tpn表达增加了表面MHC I类,并恢复了肿瘤细胞对抗原特异性CTL杀伤的敏感性,AdhTpn感染树突状细胞也显著增加了交叉呈递和交叉启动。此外,接种AdhTpn的荷瘤动物肿瘤内浸润的CD8(+)和CD4(+) T细胞以及CD11c(+)树突状细胞显著增加。引人注目的是,与载体对照相比,接种AdhTpn的同基因荷瘤小鼠肿瘤生长显著减少,生存期延长,将AdhTpn接种与AdhTAP1联合使用比单独使用任何一种成分都能显著增强对肿瘤诱导死亡的保护作用。
这是首次证明单独使用Tpn可提高生存率并增强抗肿瘤免疫力,但此外还表明Tpn和TAP应作为免疫治疗疫苗方案的成分一起使用以根除肿瘤。